Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society 68th Annual Scientific Meeting
Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month
Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2026 Annual Meeting
Fathom Announces New Zones of Mineralization Highlighting Exploration Potential of Recently Announced Gochager Lake Ni-Cu-Co Deposit Maiden MRE
Freegold Intersects 3.10 g/t Au over 102.8 m including 5.18 g/t Au over 55.9 m as it advances Golden Summit PFS
New Break Reports 3.12 g/t Au over 6.5 Metres and 1.61 g/t Au over 10.8 Metres from the Balance of Summer Drilling at Its Moray Gold Project
